These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 7735224)

  • 1. Relationship between apparent total body clearance of cyclosporin A and its erythrocyte-to-plasma distribution ratio in renal transplant patients.
    Shibata N; Minouchi T; Yamaji A; Park KI; Inoue H; Tomoyoshi T; Sako H; Abe H; Kodama M; Nakane Y
    Biol Pharm Bull; 1995 Jan; 18(1):115-21. PubMed ID: 7735224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nomogram for predicting optimal dosage of cyclosporine in renal transplant patients: taking physiological factors into consideration for regimen during immunosuppressive therapy.
    Shibata N; Hoshino N; Minouchi T; Yamaji A
    Biol Pharm Bull; 1995 Oct; 18(10):1423-9. PubMed ID: 8593449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple method for predicting the cyclosporin A erythrocyte-to-plasma distribution ratio in blood, and its clinical assessment.
    Shibata N; Yamaji A; Park K; Tomoyoshi T; Sako H; Abe H; Kodama M; Nakane Y; Hodohara K; Hosoda S
    Biol Pharm Bull; 1994 May; 17(5):709-14. PubMed ID: 7920439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of cyclosporin A after intravenous administration to rats in various disease states.
    Shibata N; Shimakawa H; Minouchi T; Yamaji A
    Biol Pharm Bull; 1993 Nov; 16(11):1130-5. PubMed ID: 8312870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isoniazid does not affect bioavailability of cyclosporine in renal transplant recipients.
    Sud K; Muthukumar T; Singh B; Garg SK; Kohli HS; Jha V; Gupta KL; Sakhuja V
    Methods Find Exp Clin Pharmacol; 2000 Oct; 22(8):647-9. PubMed ID: 11256238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vivo distribution and erythrocyte binding characteristics of cyclosporin in renal transplant patients.
    Kurokawa N; Kadobayashi M; Yamamoto K; Arakawa Y; Sawada M; Takahara S; Okuyama A; Yanaihara C
    J Pharm Pharmacol; 1996 Jun; 48(6):553-9. PubMed ID: 8832486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic behavior of cyclosporine A in liver dysfunction.
    Kihira K; Kadoyama M; Miyake K; Kitaura T; Kimura Y; Yoshida M; Fukuchi H
    Hiroshima J Med Sci; 1994 Dec; 43(4):175-8. PubMed ID: 7883584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A predictive model for area under the concentration versus time curve of cyclosporin A using several routine monitoring results in renal transplant patients.
    Shibata N; Hayakawa T; Hoshino N; Minouchi T; Yamaji A
    Biol Pharm Bull; 1997 Aug; 20(8):897-903. PubMed ID: 9300138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters.
    Takeuchi H; Okuyama K; Konno O; Jojima Y; Akashi I; Nakamura Y; Iwamoto H; Hama K; Iwahori T; Uchiyama M; Ashizawa T; Matsuno N; Nagao T; Hirano T; Oka K
    Transplant Proc; 2005 May; 37(4):1745-7. PubMed ID: 15919452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation and comparison of therapeutic monitoring of whole-blood levels of cyclosporin A and its metabolites in renal transplantation by HPLC and RIA methods.
    Safarcík K; Brozmanová H; Bartos V; Jegorov A; Grundmann M
    Clin Chim Acta; 2001 Aug; 310(2):165-71. PubMed ID: 11498082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporin in renal transplantation: a 9 year experience.
    Yuan ZF; Bailey RR; Gardner J
    N Z Med J; 1995 Feb; 108(993):29-32. PubMed ID: 7891931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythrocyte uptake and protein binding of cyclosporin A (CyA) in human blood: factors affecting CyA concentration in erythrocytes.
    Shibata N; Shimakawa H; Minouchi T; Yamaji A
    Biol Pharm Bull; 1993 Jul; 16(7):702-7. PubMed ID: 8401406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The estimation of the plasma free fraction of cyclosporine in rabbits and heart transplant patients: the application of a physiological model of renal clearance.
    Shah AK; Brundage RC; Lake KD; Sawchuk RJ
    Biopharm Drug Dispos; 1995 Jan; 16(1):59-70. PubMed ID: 7711283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of plasma lipid on pharmacokinetics of ciclosporin and its relationship with plasma prednisolone level in renal transplant patients.
    Sugioka N; Kokuhu T; Okamoto M; Yoshimura N; Ito Y; Shibata N; Takada K
    J Pharm Pharmacol; 2006 Sep; 58(9):1193-200. PubMed ID: 16945177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A preliminary pharmacokinetic study of cyclosporine A in 10 Japanese renal transplant patients.
    Takada K; Yoshikawa H; Muranishi S; Nagano S; Fukunishi T
    Int J Clin Pharmacol Ther Toxicol; 1987 Aug; 25(8):438-42. PubMed ID: 3308718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood cyclosporin concentrations but not doses correlate with acute changes in renal function following heart and heart-lung transplantation.
    Trull AK; Best NG; Tan KK; Hue KL; Higenbottam TW; Large S; Wallwork J
    Ther Drug Monit; 1992 Aug; 14(4):275-80. PubMed ID: 1519300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cremophor EL releases cyclosporin A adsorbed on blood cells and blood vessels, and increases apparent plasma concentration of cyclosporin A.
    Jin M; Shimada T; Yokogawa K; Nomura M; Mizuhara Y; Furukawa H; Ishizaki J; Miyamoto K
    Int J Pharm; 2005 Apr; 293(1-2):137-44. PubMed ID: 15778051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saturable binding of cyclosporin A to erythrocytes: estimation of binding parameters in renal transplant patients and implications for bioavailability assessment.
    Legg B; Rowland M
    Pharm Res; 1988 Feb; 5(2):80-5. PubMed ID: 3073383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients.
    Lam H; Jeffery J; Sitar DS; Aoki FY
    Ther Drug Monit; 2011 Dec; 33(6):699-704. PubMed ID: 22105586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Equivalence of cyclosporine blood level assays in patients receiving cyclosporine microemulsion or cyclosporine. The Sandoz Neoral Study Group N103.
    Pescovitz MD; Wong RL; Choc MG; Chang CT
    Clin Transplant; 1997 Oct; 11(5 Pt 1):442-5. PubMed ID: 9361938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.